EBR Systems (ASX:EBR), developer of the world's only wireless cardiac pacing device for heart failure, today reported strong commercial and clinical progress for the quarter ended Dec. 31, 2025.
During Q4, the company’s commercial momentum continued, with WiSE System implants doubling from the previous quarter.
A total of 18 commercial patients received the device, bringing the cumulative pilot and limited market release implants to 30.
Nine new purchase agreements were signed, and 11 additional physicians were trained to support broader adoption of the system.
Several implants were performed at leading centers, including the Louis Stokes Cleveland Veterans Affairs Medical Center in Ohio.
On the clinical front, EBR advanced key initiatives. The WiSE-UP post-approval study began, enrolling four patients across multiple sites to evaluate real-world outcomes of left ventricular endocardial pacing in heart failure patients.